Hospira gains global rights to Pliva/Teva's filgrastim biosimilar
This article was originally published in Scrip
Executive Summary
Hospira has acquired full worldwide rights to the biosimilar product filgrastim, a recombinant granulocyte colony stimulating factor (G-CSF), fromCroatia's Pliva (now a part of Teva Pharmaceutical Industries). Amgen's Neupogen is the innovative reference product.